Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04080115 · ClinicalTrials.gov registry record · NA

Does Increasing Attentional Control Decrease Acute Fear Response

A NA study of Attention and Fear, sponsored by Northern Illinois University.

Completed
Registry status
NA
Development phase
201
Enrollment target
1
Study location

NCT04080115: Completed NA study of Attention and Fear, sponsored by Northern Illinois University.

NCT04080115 is a NA study of Attention and Fear that has completed, run by Northern Illinois University. The registered enrollment target is 201 participants, above the 81-participant average among 13 other Attention trials with a reported enrollment target (148% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04080115, a NA study of Attention and Fear, has completed, sponsored by Northern Illinois University.

COMPLETED
Registry status
NA
Development phase
201 participants
Enrollment target
1
Study location

Study Summary

Despite decades of research, current psychological treatments designed to treat a variety of mental illnesses are not effective for all who receive them. Specifically, well-supported treatments for mental illnesses that involve fear (e.g., PTSD, panic) appear to be effective for the majority of individuals, but consistently leave a group of "treatment non-responders." One potential explanation for the observed discrepancy in treatment response may be the focus of modern psychotherapies on relieving symptoms specific to categorical diagnoses, rather than mechanisms underlying why the individual is experiencing the symptoms. Recently, fear-based psychological disorders (e.g., PTSD, specific phobia, panic disorder, social anxiety) have been identified as sharing a distinct set of biomarkers, including genetic biomarkers of acute fear (i.e., fear in the moment) and impairments in controlling attention. Neurobehavioral interventions are therefore a promising class of treatments designed to target the biological markers that may be maintaining the symptoms of various psychological disorders. The Attention Training Technique (ATT) is a neurobehavioral intervention that has garnered attention through its demonstrated effectiveness in reducing symptoms across a variety of psychological diagnoses. While grounded in well-established theory, the mechanisms of change in ATT are largely unknown. One proposed mechanism may be that ATT promotes functional connectivity between regions in the brain implicated in top-down executive control over attention (ventromedial prefrontal cortex \[vmPFC\] and dorsolateral prefrontal cortex \[dlPFC\]) and bottom-up attention networks (dorsal anterior cingulate cortex \[dACC\] and amygdala), resulting in increased top-down regulation of potentially problematic bottom-up attentional processes. The same brain regions implicated in both top-down and bottom-up attentional processes have also been associated with fear responding (i.e., startle respons

Primary Outcome

The ANT is a behavioral reaction time (RT) measure of attentional alerting, orienting, and executive control (Fan et al., 2002). The test is a combination of the commonly used flanker task (see Eriksen \& Eriksen, 1974) and a simple cued reaction time task (see Posner, 1980). The ANT provides measures of both RT and error rates (ER). There are several test conditions of interest in the ANT that produce scores that are indications of efficiency in the three separate attention networks.

Conditions Studied

Interventions

  • BEHAVIORAL Attention Training Technique
  • BEHAVIORAL Sham intervention control condition

Study Locations (1)

Illinois

  • Northern Illinois University - DeKalb

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2021-11-05
Est. Completion 2024-04-30
Phase NA
Northern Illinois University

5 total trials

What the finished NCT04080115 record still lists

NCT04080115 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 13 other Attention trials with a reported enrollment target (148% higher).

The record links to 2 conditions, with Attention appearing as the primary indexed condition, and to 2 interventions - of which Attention Training Technique is the first listed.

NCT04080115 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT04080115 about?

NCT04080115 is a clinical study titled "Does Increasing Attentional Control Decrease Acute Fear Response". Despite decades of research, current psychological treatments designed to treat a variety of mental illnesses are not effective for all who receive them. Specifically, well-supported treatments for mental illnesses that involve fear (e.g., PTSD, panic) appear to be effective for the majority of indi...

What is the current status of trial NCT04080115?

This trial is currently completed. It is a NA study. The enrollment target is 201 participants. The study started on 2021-11-05. Estimated completion is 2024-04-30.

What conditions does trial NCT04080115 study?

This clinical trial studies the following conditions: Attention, Fear.

What interventions are being tested in trial NCT04080115?

The interventions under investigation include: Attention Training Technique (BEHAVIORAL), Sham intervention control condition (BEHAVIORAL).

Who is sponsoring clinical trial NCT04080115?

This trial is sponsored by Northern Illinois University, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04080115 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04080115's enrollment target sits among peer trials

201 3rd of 13 higher than 11 of 13 other Attention trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04080115, the US trial registry maintained by the National Library of Medicine. NCT04080115 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.